Genetic-Guided Medication for Mental Health Disorders in Children
(PGx-SParK Trial)
Trial Summary
What is the purpose of this trial?
Implementation of pharmacogenetic testing for children and adolescents aged 6-24 who are starting or changing psychiatric medication.
Do I need to stop my current medications to join the trial?
The trial information does not specify if you need to stop your current medications. It focuses on starting or changing psychiatric medications, so you may be able to continue your current ones, but it's best to confirm with the trial coordinators.
What data supports the effectiveness of pharmacogenetic testing for mental health disorders in children?
Research shows that pharmacogenetic testing can improve the effectiveness of mental health treatments by tailoring medications to a child's genetic makeup, which can enhance drug efficacy and reduce side effects. Studies in youth psychiatry indicate that this personalized approach can lead to better treatment outcomes compared to the traditional trial-and-error method.12345
Is genetic-guided medication safe for children with mental health disorders?
Pharmacogenetic testing, which helps tailor medications based on a person's genetic makeup, has shown promise in making drug treatments safer by reducing side effects and adverse reactions. This approach is particularly useful for children who take multiple medications and are at higher risk for side effects.12367
How is pharmacogenetic testing different from other treatments for mental health disorders in children?
Research Team
Chad Bousman
Principal Investigator
University of Calgary
Eligibility Criteria
This trial is for children and adolescents aged 6-24 in Alberta, British Columbia, Saskatchewan, or Manitoba who are starting or changing psychiatric medication. They must have medical records available and a licensed psychiatrist or physician requesting the test. Those with unstable health conditions, inability to consent, reluctance to give a saliva sample, or history of certain transplants cannot join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Pharmacogenetic Testing
Implementation of pharmacogenetic testing for children and adolescents starting or changing psychiatric medication
Follow-up
Participants are monitored for safety and effectiveness after pharmacogenetic testing
Treatment Details
Interventions
- Pharmacogenetic Testing
Pharmacogenetic Testing is already approved in United States, Canada, European Union for the following indications:
- Guidance for certain medications like carbamazepine, valproic acid, and tetrabenazine
- Guidance for certain medications like carbamazepine, valproic acid, and tetrabenazine
- Guidance for certain medications, but specific indications vary by country
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Calgary
Lead Sponsor